Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • López-Millán, Belén|||0000-0002-9757-5454
  • Lavoie, Jessie R.
  • Bueno, Clara|||0000-0003-1442-6216
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Gómez-Casares, Maite
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Juan, Manel|||0000-0002-3064-1648
  • Delgado, Julio|||0000-0002-5157-4376
  • Blanco, Maria L.
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Chaparro, Alberto
  • Fuster, José Luis|||0000-0002-4881-9440
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Rosu-Myles, Michael
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Bone marrow mesenchymal stem/stromal cells (BM-MSCs) are key components of the hematopoietic niche thought to have a direct role in leukemia pathogenesis. BM-MSCs from patients with acute myeloid leukemia (AML) have been poorly characterized due to disease heterogeneity. We report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified by molecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. Stable MSC cultures were successfully established and characterized from 40 of 46 AML patients irrespective of the risk subgroup. AML-derived BM-MSCs never harbored tumor-specific cytogenetic/molecular alterations present in blasts, but displayed higher clonogenic potential than healthy donor (HD)-derived BM-MSCs. Although HD- and AML-derived BM-MSCs equally provided chemoprotection to AML cells in vitro, AML-derived BM-MSCs were more immunosuppressive/anti-inflammatory, enhanced suppression of lymphocyte proliferation, and diminished secretion of pro-inflammatory cytokines. Multivariate analysis revealed that the level of interleukin-10 produced by AML-derived BM-MSCs as an independent prognostic factor negatively affected overall survival. Collectively our data show that AML-derived BM-MSCs are not tumor related, but display functional differences contributing to therapy resistance and disease evolution. In this article, Díaz de la Guardia and colleagues report a functional, genetic, and immunological characterization of BM-MSC cultures from 46 AML patients, stratified by molecular/cytogenetics into low-risk (LR), intermediate-risk (IR), and high-risk (HR) subgroups. BM-MSCs never harbored tumor-specific cytogenetic/molecular alterations present in blasts, and IL-10 produced by AML-derived BM-MSCs is an independent prognostic factor negatively impacting on overall survival.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells

  • Godfrey, Laura|||0000-0002-6222-3563
  • Crump, Nicholas|||0000-0001-9610-6763
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Lau, I. Jun
  • Rice, Siobhan
  • Harman, Joe R.
  • Jackson, Thomas
  • Elliott, Natalina|||0000-0002-6713-7349
  • Buck, Gemma
  • Connor, Christopher
  • Thorne, Ross
  • Knapp, David J. H. F.
  • Heidenreich, Olaf|||0000-0001-5404-6483
  • Vyas, Paresh
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Inglott, Sara
  • Ancliff, Philip
  • Geng, Huimin
  • Roberts, Irene|||0000-0002-6094-6397
  • Roy, Anindita
  • Milne, Thomas|||0000-0002-0413-4271
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer-promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.